021-51111890
购物车（）
sales@molnova.cn
Ubrogepant
CAS No. 1374248-77-7
Ubrogepant ( MK-1602;MK1602 )
产品货号. M11544 CAS No. 1374248-77-7
Ubrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥3937 | 有现货 |
|
| 10MG | ￥6261 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Ubrogepant
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Ubrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine.
-
产品描述Ubrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine.Migraine Phase 3 Clinical
-
同义词MK-1602;MK1602
-
通路GPCR/G Protein
-
靶点CGRP Receptor
-
受体CGRP Receptor
-
研究领域Neurological Disease
-
适应症Migraine
化学信息
-
CAS Number1374248-77-7
-
分子量549.55
-
分子式C29H26F3N5O3
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESO=C(C1=CN=C2C(C[C@@]3(C4=CC=CN=C4NC3=O)C2)=C1)N[C@@H]5C(N(CC(F)(F)F)[C@H](C)[C@H](C6=CC=CC=C6)C5)=O
-
化学全称(3'S)-1',2',5,7-Tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxospiro[6H-cyclopenta[b]pyridine-6,3'-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Li CC, et al. J Clin Pharmacol. 2017 Nov 14. doi: 10.1002/jcph.1021.
2. Holland PR, et al. Neurotherapeutics. 2018 Apr;15(2):304-312.
3. Voss T, et al. Cephalalgia. 2016 Aug;36(9):887-98.
2. Holland PR, et al. Neurotherapeutics. 2018 Apr;15(2):304-312.
3. Voss T, et al. Cephalalgia. 2016 Aug;36(9):887-98.
产品手册
关联产品
-
PHM 27 (human)
Endogenous peptide product of human prepro-VIP and analog of porcine PHI-27; potent agonist for the human calcitonin receptor (EC50 = 11 nM). Transgenic mice expressing the human VIP/PHM 27 gene in pancreatic β-islets display enhanced glucose-induced insulin secretion.
-
MK-3207
A highly potent, selective CGRP receptor antagonist with Ki of 21 pM in in vitro binding assay and IC50 of 0.12 nM in cell-based functional assay.
-
MK-0974
A potent, selective, orally bioavailable CGRP receptor antagonist with Ki of 0.77 nM.
